We are live on ! Find out more
CSCI

COSCIENS Biopharma

Delisted

CSCI was delisted on the 3rd of September, 2025.

16 hedge funds and large institutions have $1.3M invested in COSCIENS Biopharma in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $482K | Put options by funds: $153K

7% more funds holding

Funds holding: 15 → 16 (+1)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

4.96% less ownership

Funds ownership: 8.11% → 3.15% (-5%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

90% less capital inflows, than outflows

Capital inflows: $193K | Capital outflows: $1.89M

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
4
Closed
4
Calls
$482​K
Puts
$153​K
Net Calls
+$329​K
Net Calls Change
+$512​K

CSCI Hedge Fund Activity: Q1 2017 in Review

16 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma (CSCI) for Q1 2017, worth a combined $1.3M — down 63% from $3.48M a quarter earlier.

Fund positioning in CSCI was balanced in Q1 2017: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $150K. The largest seller was Sabby Management, exiting entirely with an estimated $1.18M sold.

  • 16 institutional investors held COSCIENS Biopharma (CSCI) as of Q1 2017, up from 15 in Q4 2016.
  • Funds reported $1.3M of COSCIENS Biopharma stock for Q1 2017, down 63% quarter-over-quarter.
  • 4 funds opened new COSCIENS Biopharma positions in Q1 2017 and 4 closed out, a net change of 0 holders.
  • The largest COSCIENS Biopharma buyer in Q1 2017 was Susquehanna International Group, an estimated $150K added.
  • The largest COSCIENS Biopharma seller in Q1 2017 was Sabby Management, an estimated $1.18M sold.

Based on aggregated 13F filings for Q1 2017.